January 11, 2021 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships Product Launch

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO–(BUSINESS WIRE)–With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina... Read more

January 6, 2021 Lab Top-10 Licensing, IP, and Legal Product Launch

Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions

Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions New model for instrument and equipment procurement offers customers subscription-based access to technology, and associated consumables, services and support WALTHAM, Mass., Jan. 6, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment... Read more

January 4, 2021 Licensing, IP, and Legal

HORIBA Scientific Completes Healthy Business Certification

01/04/2021 NJBIA Certifies HORIBA NJ Office as a Certified Site for Infectious Disease Prevention Piscataway, NJ – January 4th, 2021  HORIBA Scientific, global leader in measurement and analysis solutions for research and industry, is proud to announce that the Piscataway, New Jersey office has completed the requirements of the NJBIA program to achieve the Healthy Business... Read more

January 4, 2021 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal Mass Spectrometry

Bruker Introduces MBT Sepsityper® Kit US IVD for Rapid and Affordable Identification of over 400 Microorganisms from Positive Blood Cultures

MBT Sepsityper Kit US IVD enables rapid, specific detection of many cases of bacteremia-induced sepsis to assist infectious disease specialists in potentially life-saving decisions Used for MALDI Biotyper® (MBT) identification directly from Positive Blood Cultures (PBC) with short time-to-result (TTR) of less than 30 minutes US FDA clearance received in late December for diagnostic use... Read more

December 28, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Quanterix Receives FDA Emergency Use Authorization for Semi-quantitative Antibody Test

Infectious Disease Technology Antibody test available on Simoa HD-X Analyzer® detects and quantitates IgG antibodies to SARS-CoV-2 in serum or EDTA plasma   BILLERICA, Mass., December 28, 2020 – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use... Read more

December 14, 2020 Acad, Gov/Utilities Licensing, IP, and Legal

FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis

Basel, 14 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The... Read more

December 8, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

December 8, 2020 at 10:17 AM EST CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. The... Read more

December 8, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

LGC’s Anti-SARS-CoV-2 controls kit now CE Marked

LGC is pleased to announce that the ACCURUN® Anti-SARS-CoV-2 Reference Material Kit is now CE marked for in vitro diagnostic use (CE-IVD). With this change in regulatory status, the new product name is ACCURUN Anti-SARS-CoV-2 Controls Kit. Bearing the CE mark and IVD symbol signifies that the ACCURUN Anti-SARS-CoV-2 Controls Kit meets extensive design control requirements. ACCURUN... Read more